Lumida
/RCEL
⌘K
AVITA Medical Inc

AVITA Medical Inc

RCEL
$9.88USD↑+0.20%+0.02 today

MARKET CAP

305.6M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$10 – $10

52W RANGE

$3
$11

AI Summary

Stalk
TrimMedium

RCEL remains in a sustained Stage 4 decline with persistent lower highs and lower lows and price below all key moving averages. Oversold conditions at current levels increase the risk of a bounce, so under the speculative strategy we defer selling to rallies into resistance around the EMAs to ensure asymmetric entry.

  • ↑Q2 revenue of $21.7M grew 18% YoY driven by RECELL sales.
  • ↑Full-year 2026 revenue guidance boosted to $86–89M with Q4 cash-flow breakeven forecast.
  • ↓Negative earnings yield and weak book-to-price suggest rich valuation.
Full analysis →

Buying

3

institutions

Selling

2

institutions

New Positions

1

this quarter

Filing Period

Q2 2026

latest 13-F

13-F Holdings

Institution↕Action↕Shares Held↕Value↓Change↕Chg %↕Weight↕
BI

Blackrock, Inc.

Q2 2026

SELL564.95 K2.33 M+-568.17 K-44.4%0.00%
AC

Aqr Capital Management LLC

Q2 2026

BUY321.01 K1.33 M+226.65 K+279.7%0.00%
CA

Citadel Advisors LLC

Q2 2026

BUY37.05 K153.00 K+11.42 K+61.4%0.00%
MM

Millennium Management LLC

Q2 2026

BUYNEW15.43 K63.72 K+15.43 K+0.0%0.00%
JC

Jpmorgan Chase & Co

Q2 2026

SELL2.23 K9.49 K+-3.68 K-55.8%0.00%